Ije Nwokori Purchases 112,500 Shares of Dr. Martens (LON:DOCS) Stock

Dr. Martens plc (LON:DOCS) insider Ije Nwokori acquired 112,500 shares of Dr. Martens stock in a transaction on Friday, June 12th. The shares were bought at an average price of GBX 76 per share, for a total transaction of £85,500.

Ije Nwokori also recently made the following trade(s):

• On Thursday, June 11th, Ije Nwokori bought 202 shares of Dr. Martens stock. The stock was bought at an average price of GBX 74 per share, with a total value of £149.48.
• On Wednesday, May 13th, Ije Nwokori bought 233 shares of Dr. Martens stock. The shares were bought at an average price of GBX 64 per share, for a total transaction of £149.12.
• On Wednesday, April 15th, Ije Nwokori sold 204,051 shares of Dr. Martens stock. The stock was sold at an average price of GBX 66, for a total value of £134,673.66.
• On Tuesday, April 14th, Ije Nwokori purchased 232 shares of Dr. Martens stock. The shares were bought at an average cost of GBX 65 per share, for a total transaction of £150.80.

Dr. Martens Stock Up 0.6%

LON DOCS traded up GBX 0.40 on Tuesday, reaching GBX 72.50. The company had a trading volume of 377,685 shares, compared to its average volume of 8,721,683. The company has a debt-to-equity ratio of 108.27, a current ratio of 2.61 and a quick ratio of 1.13. Dr. Martens plc has a 1 year low of GBX 59.15 and a 1 year high of GBX 100.87. The firm has a 50-day moving average of GBX 67.35 and a 200-day moving average of GBX 69.69. The firm has a market capitalization of £693.89 million, a PE ratio of 30.21, a P/E/G ratio of 6.40 and a beta of 0.25.

Dr. Martens (LON:DOCS) last posted its quarterly earnings data on Tuesday, May 19th. The company reported GBX 4.20 earnings per share (EPS) for the quarter. Dr. Martens had a net margin of 3.11% and a return on equity of 6.89%. The company had revenue of £764.90 million for the quarter. On average, equities research analysts anticipate that Dr. Martens plc will post 2.5809394 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on DOCS. Royal Bank Of Canada reiterated a “sector perform” rating and issued a GBX 100 price objective on shares of Dr. Martens in a report on Tuesday, June 2nd. Berenberg Bank lowered their target price on Dr. Martens from GBX 114 to GBX 110 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of GBX 105.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.